Facebook Instagram Pinterest Reddit Tumblr X Youtube
  • Home
  • About
  • News
  • Events
  • Shop
  • Directory
  • Contact Us
Search
Sign in
Welcome! Log into your account
Forgot your password? Get help
Password recovery
Recover your password
A password will be e-mailed to you.
PsyNews.com
  • Home
  • About
  • News
  • Events
  • Shop
  • Directory
  • Contact Us
Home Featured Page 138

Featured

Latest
  • Latest
  • Featured posts
  • Most popular
  • 7 days popular
  • By review score
  • Random

The Psychedelic Practitioner Issue 6: Preparedness (People)

Two Years After Rejection, Resilient Quietly Refiles MDMA for PTSD Application

Smooth Sailing: Definium’s LSD Voyage Hits Primary and Key Secondary Endpoints in GAD

Weekly Psychedelic Policy Briefing – August 9, 2026

Ibogaine’s Moment Has Arrived. Are We Ready to Meet It?

The Psychedelic Value Chain

Psychedelics Weekly – Client Data Concerns in Oregon, Hopeful Legalization in...

Israel-Based Clearmind Successfully Completed Two R&D Projects With The Hebrew University...

Bexson Biomedical Issued USPTO Patent on Proprietary Formulation Technology, SEVALENT™

Revive Therapeutics Submits Updated Briefing Package in Support of Upcoming Type...

MYDECINE INNOVATIONS GROUP FILES PROSPECTUS SUPPLEMENT AND ANNOUNCES CLOSING UNDER SHARE...

FILAMENT HEALTH ANNOUNCES CLINICAL TRIAL APPROVAL IN PARTNERSHIP WITH PSYCHIATRIC CENTRE...

Numinus Wellness Inc. Reports Q1 2023 Results

Insuring Psychedelics: The Missing Link

“After the Ecstasy, the Laundry” – Shayla Love’s Take on Psychedelics...

Load more

EDITOR PICKS

The Psychedelic Practitioner Issue 6: Preparedness (People)

Two Years After Rejection, Resilient Quietly Refiles MDMA for PTSD Application

Smooth Sailing: Definium’s LSD Voyage Hits Primary and Key Secondary Endpoints...

POPULAR POSTS

How to Get DMT: Obtaining the Spirit Molecule

Having Sex on DMT: What You Need to Know

DMT Pricing Guide

POPULAR CATEGORY

    ABOUT US
    PsyNews.com has a single-sector focus. We are a news platform dedicated to covering the psychedelic industry. This includes companies, startups, venture capital firms, investment banks, pharma, research, etc, anything associated with the new emerging industry and asset class. Many of the chemicals and compounds involved are LSD, psilocybin, DMT, ketamine, MDMA, ecstasy, ibogaine, analogs, derivatives, psychedelic mushrooms, fungi, psilocin, entheogens, empathogens, indocybin, magic truffles (psilocybin sclerotia), etc. They range from classical and standard to new and exotic. PsyNews.com will cover all psychedelic news in the psy industry, including current events, updates, and what’s happening everywhere in the sector in term of developments and investments. We will be tracking companies worth, valuation, ROI, financials, stock, revenue, IPO’s, and more. Along with medical, recreational, clinical trials, FDA, mindfulness, psy space, 5-HT2A receptor experiments, and so forth. Join us on an unforgettable journey to the center of the psychedelic industry.
    FOLLOW US
    Facebook Instagram Pinterest Reddit Tumblr X Youtube
    ©